DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Orap (Pimozide) - Indications and Dosage

 
 



INDICATIONS AND USAGE

ORAP (pimozide) is indicated for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment. ORAP is not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. ORAP should be reserved for use in Tourette's Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics.

Evidence supporting approval of pimozide for use in Tourette's Disorder was obtained in two controlled clinical investigations which enrolled patients between the ages of 8 and 53 years. Most subjects in the two trials were 12 or older.

DOSAGE AND ADMINISTRATION

GENERAL

The suppression of tics by ORAP requires a slow and gradual introduction of the drug. The patient's dose should be carefully adjusted to a point where the suppression of tics and the relief afforded is balanced against the untoward side effects of the drug.

An ECG should be done at baseline and periodically thereafter especially during the period of dose adjustment (see WARNINGS and PRECAUTIONS -- Laboratory Tests). Periodic attempts should be made to reduce the dosage of ORAP to see whether or not tics persist at the level and extent first identified. In attempts to reduce the dosage of ORAP, consideration should be given to the possibility that increases of tic intensity and frequency may represent a transient, withdrawal-related phenomenon rather than a return of disease symptoms. Specifically, one to two weeks should be allowed to elapse before one concludes that an increase in tic manifestations is a function of the underlying disease syndrome rather than a response to drug withdrawal. A gradual withdrawal is recommended in any case.

CHILDREN

Reliable dose response data for the effects of ORAP (pimozide) on tic manifestation in Tourette's Disorder patients below the age of twelve are not available.

Treatment should be initiated at a dose of 0.05 mg/kg preferably taken once at bedtime. The dose may be increased every third day to a maximum of 0.2 mg/kg not to exceed 10 mg/day.

ADULTS

In general, treatment with ORAP should be initiated with a dose of 1 to 2 mg a day in divided doses. The dose may be increased thereafter every other day. Most patients are maintained at less than 0.2 mg/kg per day, or 10 mg/day, whichever is less. Doses greater than 0.2 mg/kg/day or 10 mg/day are not recommended.

HOW SUPPLIED

ORAP® (pimozide) 1 mg tablets are white, oval, scored tablets, debossed "ORAP 1". They are available in bottles of 100 (NDC 57844-151-01).

ORAP® (pimozide) 2 mg tablets are white, oval, scored tablets, debbosed "LEMMON" on one side and "ORAP 2" on the other. They are available in bottles of 100 (NDC 57844-187-01).

Store at controlled room temperature 15°-30°C (59°-86°F).

Dispense in a tight, light-resistant container as defined in the official compendum.

Pharmacist: Dispense in child-resistant container.

Manufactured for:

GATE PHARMACEUTICALS

Div. of TEVA Pharmaceuticals USA

Sellersville, PA 18960

Manufactured by:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Rev. J 8/99

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017